非中和抗体能够抑制1型人类免疫缺陷病毒在巨噬细胞和未成熟树突状细胞中的复制。
Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.
作者信息
Holl Vincent, Peressin Maryse, Decoville Thomas, Schmidt Sylvie, Zolla-Pazner Susan, Aubertin Anne-Marie, Moog Christiane
机构信息
EA 3770, ULP, Institut de Virologie, 3 rue Koeberlé, F-67000 Strasbourg, France.
出版信息
J Virol. 2006 Jun;80(12):6177-81. doi: 10.1128/JVI.02625-05.
Abstract
Only five monoclonal antibodies (MAbs) neutralizing a broad range of primary isolates (PI) have been identified up to now. We have found that some MAbs with no neutralizing activities according to the "conventional" neutralization assay, involving phytohemagglutinin-stimulated peripheral blood mononuclear cells as targets, efficiently inhibit the replication of human immunodeficiency virus type 1 (HIV-1) PI in macrophages and immature dendritic cells (iDC). The mechanism of inhibition is distinct from the neutralization of infectivity occurring via Fab fragments and involves the interaction of the F portion with the FcgammaRs present on macrophages and iDC. We propose that, if such nonneutralizing inhibitory antibodies limit mucosal HIV transmission, they should be induced by vaccination.
摘要
截至目前，仅发现五种能中和多种原始分离株（PI）的单克隆抗体（MAb）。我们发现，一些根据“传统”中和试验无中和活性的单克隆抗体，以植物血凝素刺激的外周血单核细胞为靶点，可有效抑制1型人类免疫缺陷病毒（HIV-1）原始分离株在巨噬细胞和未成熟树突状细胞（iDC）中的复制。抑制机制不同于通过Fab片段发生的感染性中和，涉及F部分与巨噬细胞和iDC上存在的FcγRs的相互作用。我们提出，如果此类非中和性抑制抗体限制黏膜HIV传播，那么它们应通过疫苗接种来诱导产生。
相似文献
1
Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.
J Virol. 2006 Jun;80(12):6177-81. doi: 10.1128/JVI.02625-05.
2
Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages.
J Immunol. 2004 Nov 15;173(10):6274-83. doi: 10.4049/jimmunol.173.10.6274.
3
Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation.
Blood. 2006 Jun 1;107(11):4466-74. doi: 10.1182/blood-2005-08-3490. Epub 2006 Feb 9.
4
Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Virology. 1997 Mar 17;229(2):360-9. doi: 10.1006/viro.1997.8443.
5
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
J Virol. 1998 Dec;72(12):9788-94. doi: 10.1128/JVI.72.12.9788-9794.1998.
6
Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production.
Sci Rep. 2014 Aug 18;4:5845. doi: 10.1038/srep05845.
7
Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.
J Virol. 2001 Mar;75(5):2235-45. doi: 10.1128/JVI.75.5.2235-2245.2001.
8
HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies.
J Virol. 2011 Jan;85(2):1077-85. doi: 10.1128/JVI.01619-10. Epub 2010 Nov 17.
9
Follicular dendritic cells and human immunodeficiency virus infectivity.
Nature. 1995 Oct 26;377(6551):740-4. doi: 10.1038/377740a0.
10
A nonneutralizing anti-HIV Type 1 antibody turns into a broad neutralizing antibody when expressed on the surface of HIV type 1-susceptible cells. II. Inhibition of HIV type 1 captured and transferred by DC-SIGN.
AIDS Res Hum Retroviruses. 2006 Sep;22(9):874-83. doi: 10.1089/aid.2006.22.874.
引用本文的文献
1
Unpredicted Protective Function of Fc-Mediated Inhibitory Antibodies for HIV and SARS-CoV-2 Vaccines.
J Infect Dis. 2025 Feb 4;231(1):e1-e9. doi: 10.1093/infdis/jiae464.
2
3
The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine.
Res Sq. 2024 Apr 22:rs.3.rs-4139764. doi: 10.21203/rs.3.rs-4139764/v1.
4
Fc receptors and the diversity of antibody responses to HIV infection and vaccination.
Genes Immun. 2022 Aug;23(5):149-156. doi: 10.1038/s41435-022-00175-7. Epub 2022 Jun 10.
5
The TZM-bl Reporter Cell Line Expresses Kynureninase That Can Neutralize 2F5-like Antibodies in the HIV-1 Neutralization Assay.
Int J Mol Sci. 2022 Jan 7;23(2):641. doi: 10.3390/ijms23020641.
6
A new lease on life for an HIV-neutralizing antibody class and vaccine target.
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7). doi: 10.1073/pnas.2026390118.
7
Increased vaccine tolerability and protection via NF-κB modulation.
Sci Adv. 2020 Sep 9;6(37). doi: 10.1126/sciadv.aaz8700. Print 2020 Sep.
8
Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization.
Front Immunol. 2019 Dec 18;10:2968. doi: 10.3389/fimmu.2019.02968. eCollection 2019.
9
Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.
Cell Rep. 2019 Jul 23;28(4):877-895.e6. doi: 10.1016/j.celrep.2019.06.074.
10
Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV.
Curr Opin HIV AIDS. 2019 Jul;14(4):309-317. doi: 10.1097/COH.0000000000000551.
本文引用的文献
1
Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation.
Blood. 2006 Jun 1;107(11):4466-74. doi: 10.1182/blood-2005-08-3490. Epub 2006 Feb 9.
2
Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
J Virol. 2005 Nov;79(21):13338-49. doi: 10.1128/JVI.79.21.13338-13349.2005.
3
Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41.
Virology. 2005 Mar 1;333(1):102-13. doi: 10.1016/j.virol.2004.12.034.
4
HIV-1 and the hijacking of dendritic cells: a tug of war.
Springer Semin Immunopathol. 2005 Jan;26(3):309-28. doi: 10.1007/s00281-004-0178-y.
5
Neutralizing antibody quantification by flow cytometry.
Methods Cell Biol. 2004;75:709-16. doi: 10.1016/s0091-679x(04)75030-x.
6
Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages.
J Immunol. 2004 Nov 15;173(10):6274-83. doi: 10.4049/jimmunol.173.10.6274.
7
Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15131-6. doi: 10.1073/pnas.2436476100. Epub 2003 Nov 19.
8
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.
AIDS Res Hum Retroviruses. 2003 Mar;19(3):177-86. doi: 10.1089/088922203763315678.
9
Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.
Antiviral Res. 2002 Aug;55(2):209-25. doi: 10.1016/s0166-3542(02)00052-9.
10
Neutralizing antibodies against HIV -- back in the major leagues?
Curr Opin Immunol. 2002 Aug;14(4):495-502. doi: 10.1016/s0952-7915(02)00362-x.
Zotero 插件